Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3413]
News [7789]
Articles [63]
Editorials [9]
Conferences [208]
elearning [49]
Nivolumab and ipilimumab combination for advanced skin cancer
Dr James Larkin - The Royal Marsden, London, UK
Nivolumab and ipilimumab combination for advanced skin cancer ( Dr James Larkin - The Royal Marsden, London, UK )
12 Apr 2017
Long-term clinical outcomes and analyses of atezolizumab for mTNBC
Prof Peter Schmid - Barts Cancer Institute, London, UK
Long-term clinical outcomes and analyses of atezolizumab for mTNBC ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
12 Apr 2017
Checkmate 067 - combined nivolumab and ipilimumab
Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Checkmate 067 - combined nivolumab and ipilimumab ( Dr Suzanne Topalian - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
12 Apr 2017
Durable responses to avelumab in patients with Merkel cell carcinoma
Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA
Durable responses to avelumab in patients with Merkel cell carcinoma ( Dr Howard Kaufman - Rutgers Cancer Institute of New Jersey, New Brunswick, USA )
12 Apr 2017
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors
Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA
IDH metabolites induce a BRCAness that can be exploited by PARP inhibitors ( Dr Ranjit Bindra - Yale School of Medicine, New Haven, USA )
12 Apr 2017
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker...
Prof Peter Schmid - Barts Cancer Institute, London, UK
Atezolizumab in metastatic TNBC: Long-term clinical outcomes and biomarker analyses ( Prof Peter Schmid - Barts Cancer Institute, London, UK )
11 Apr 2017
Five-year follow-up of nivolumab in NSCLC
Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA
Five-year follow-up of nivolumab in NSCLC ( Prof Julie Brahmer - Sidney Kimmel Comprehensive Cancer Center, Baltimore, USA )
11 Apr 2017
Final overall survival analysis of MONARCH 1
Dr Hope Rugo - UCSF Medical Center, San Francisco, USA
Final overall survival analysis of MONARCH 1 ( Dr Hope Rugo - UCSF Medical Center, San Francisco, USA )
11 Apr 2017
Redefining tamoxifen for breast cancer
Gokul Das - Roswell Park Cancer Institute, Buffalo, USA
Redefining tamoxifen for breast cancer ( Gokul Das - Roswell Park Cancer Institute, Buffalo, USA )
11 Apr 2017
Olaparib and temozolomide for relapsed small cell lung cancer
Dr Anna Farago - Massachusetts General Hospital, Boston, USA
Olaparib and temozolomide for relapsed small cell lung cancer ( Dr Anna Farago - Massachusetts General Hospital, Boston, USA )
10 Apr 2017
Final results of the HERACLES trial in HER2-amplified colorectal cancer
Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Final results of the HERACLES trial in HER2-amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017
Treatment choices for HER2 amplified colorectal cancer
Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy
Treatment choices for HER2 amplified colorectal cancer ( Dr Silvia Marsoni - Candiolo Cancer Institute, Turin, Italy )
10 Apr 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation